热门资讯> 正文

Mereo BioPharma与私人控股的âshibio签署许可协议

2025-08-19 21:43

Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2.
According to the deal, āshibio will take charge of the global clinical development of vantictumab for both adult and pediatric patients.
āshibio will have exclusive rights to develop and market vantictumab in the U.S. and other regions worldwide, except for Europe, where Mereo will maintain its commercial rights.

More on Mereo BioPharma Group

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy
Seeking Alpha’s Quant Rating on Mereo BioPharma Group
Historical earnings data for Mereo BioPharma Group
Financial information for Mereo BioPharma Group

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。